SYKES ELECTROLYTE SOLUTION COMPOUND SODIUM LACTATE HARTMANNS (SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM LACTATE AND CALCIUM CHLORIDE) SOLUTION [SYPHARMA PTY LTD]

SYKES ELECTROLYTE SOLUTION COMPOUND SODIUM LACTATE HARTMANNS (SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM LACTATE AND CALCIUM CHLORIDE) SOLUTION [SYPHARMA PTY LTD]
PDF | XML

NDC 86043-1001-1, 86043-1001-2, 86043-1001-3, 86043-1001-4, 86043-1001-5
Set ID 594f78df-11c4-4a32-80ae-07c22d1c9cb1
Category PRESCRIPTION ANIMAL DRUG LABEL
Packager Sypharma Pty Ltd
Generic Name
Product Class
Product Number
Application Number
  • STERILE NONPYROGENIC SOLUTION For Animal Use Only

  • Description

    Sykes Electrolyte Solution Compound Sodium Lactate (Hartmanns Solution) is a sterile, non-pyrogenic solution intended for fluid and electrolyte replenishment in single dose containers. May be administered intravenously, subcutaneously or intraperitoneally (except in horses) using aseptic technique. It contains no antimicrobial agents. Discard any unused portion. Composition, osmolarity, pH and ionic concentration are shown in Table 1.

    Table 1

    Composition (g/L)Sodium ChloridePotassium Chloride Calcium ChlorideSodium Lactate*
     6.0 0.40 0.28 3.24
      Ionic Concentration (mEq/L)SodiumPotassium Calcium ChlorideLactate 
     131 5 2 111 29

    *Sodium Lactate USP (S)-enantiomer

    Osmolarity (mOsmol/L) (calc): 280mOsmol per litre

    pH: 6.5 (limit 6.0 to 7.0)

    The container is free of PVC and phthalates. The container meets the requirements of USP and is registered with US FDA.

  • Clinical Pharmacology

    A multiple electrolyte intravenous solution is intended to restore the electrolyte balance and water for hydration. A combination of multiple electrolytes and sodium lactate, an alkalinizing agent, will provide electrolyte balance and normalize the pH of the acid-base of the physiological system.

  • Indications

    Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann’s Solution) is indicated as a source of water and electrolytes for all species. It is also used as an alkalinizing agent.

  • Contraindications

    Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann’s Solution) is contraindicated in patients with a known hypersensitivity to sodium lactate; congestive heart failure or severe impairment of renal function; clinical states in which the administration of sodium and chloride is detrimental.

  • Warnings

    The introduction of additives to any solution, regardless of type of container, requires special attention to ensure that no incompatibilities result. While some incompatibilities are readily absorbed, one must be aware that subtle physical, chemical and pharmacological incompatibilities can occur. The medical literature, the package insert and other available sources of information should be reviewed for thorough understanding of possible incompatibilities.

    Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann’s Solution) should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there exists edema and sodium retention.

    Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann’s Solution) should be used with great care, if at all, in patients with hyperkalemia, severe renal failure, and in conditions in which potassium retention is present.

    Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann’s Solution) should be used with great care in patients with metabolic or respiratory alkalosis. The administration of lactate ions should be done with great care in those conditions in which there is an increased level or an impaired utilization of these ions, such as severe hepatic insufficiency.

    Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann’s Solution) should not be administered simultaneously with blood through the same administration set because of likelihood of coagulation.

    The intravenous administration of Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann’s Solution) can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, over-hydration, congested states, or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of the injections. The risk of solute overloading causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of the injections.

    In patients with diminished renal function, administration of Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann’s Solution) may result in sodium or potassium retention.

    Do not administer to horses by intraperitoneal injection. Do not administer to animals with inadequate renal function. Not for use in lactic acidosis.

  • Adverse Reactions

    Adverse reactions may occur due to the solution or the technique of administration including fever response, infection at the site of injection or allergic reactions. Prolonged intravenous infusion of this type of product may cause venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia.

    If an adverse reaction does occur, discontinue the infusion and evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.

  • Precautions

    This is a single dose unit. It contains no preservatives. Use entire contents when first opened.

    Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid base balance during prolonged therapy or whenever the condition of the patient warrants such evaluation.

    Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann’s Solution) should be used with caution. Excess administration may result in metabolic alkalosis.

    Do not administer unless solution is clear and both seal and container are intact.

    Solution must be warmed to body temperature prior to administration and administered at a slow rate. Use solution promptly following initial entry.

    Reactions which may occur because of the solution or the technique of administration, include febrile response, infection at the site of injection, extravasation, and hypervolemia.

    If an adverse reaction does occur, discontinue the infusion and evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.

  • Dosage and Administration

    To be used as directed by a licensed veterinarian. The dosage of the Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann’s Solution) is dependent upon the age, weight and clinical conditions of the patient as well as laboratory determinations. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.

    For use in one patient on one occasion only. Discard any unused portion. Care should be taken with administration technique to avoid administration site reactions and infection.

    Additives may be incompatible. Complete information is not available. Those additives known to be incompatible should not be used. Consult with Pharmacist, if available. If, in the informed judgement of the doctor, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives.

  • Over-dosage

    In an event of over-hydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. See Warnings, Precautions and Adverse Events.

  • Packs Supplied

    Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann’s Solution) in plastic container is available as follows:

    Size (mL)

    Item Code

    NDC

    250

    FPHARTUS25

    86043-1001-1

    500

    FPHARTUS50

    86043-1001-2

    1000

    FPHARTUS01

    86043-1001-3

    3000

    FPHARTUS03

    86043-1001-4

    5000

    FPHARTUS05

    86043-1001-5

    Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (30°C/86°F). Protect from freezing.

  • Directions for use of plastic container

    To Open

    Tear overwrap at slit and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing solution container firmly. If leaks are found, discard solution as sterility may be impaired. If supplemental medication is desired, follow directions below:

    Preparation for Administration

    1. Suspend container from eyelet support.
    2. Remove plastic protector from inlet/outlet port at bottom of container.
    3. Attach administration set.

    To Add Medication

    WARNING: Additives may be incompatible.

    To add medication before solution administration

    1. Prepare medication site.
    2. Using syringe with 0.63mm to 0.80mm needle, puncture medication port and inject.
    3. Mix solution and medication thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.

    To add medication during solution administration

    1. Close the clamp on the administration set.
    2. Prepare medication site.
    3. Using syringe with 0.63mm to 0.80mm needle, puncture medication port and inject.
    4. Remove container from IV pole and/or turn to an upright position.
    5. Evacuate both ports by squeezing them while container is in the upright position.
    6. Mix solution and medication thoroughly.
    7. Return container to in use position and continue administration.

    CAUTION: FEDERAL LAW RESTRICTS THIS DRUG TO USE BY OR ON THE ORDER OF A LICENSED VETERINARIAN.

    Made in Australia

    Manufactured and distributed by:

    Sypharma Pty Ltd

    27 Healey Road Dandenong

    Victoria 3175 Australia

    For customer service email:

    customerservice@sypharma.com.au

    Version: US_01

  • Australian Label

    Current Australian Label

    Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann's Solution) 250mL Label

    Hartmanns 250mL

    Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann's Solution) 500mL Label

    Hartmanns 500mL

    Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann's Solution) 1000mL Label

    Hartmanns 1000mL

    Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann's Solution) 3000mL Label

    Hartmanns 3000mL

    Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann's Solution) 5000mL Label Version 2

    Hartmanns 5000mL

    Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann's Solution) 5000mL Label Version 1

    Hartmanns 5000mL

  • INGREDIENTS AND APPEARANCE
    SYKES ELECTROLYTE SOLUTION COMPOUND SODIUM LACTATE HARTMANNS 
    sodium chloride, potassium chloride, sodium lactate and calcium chloride solution
    Product Information
    Product TypePRESCRIPTION ANIMAL DRUGItem Code (Source)NDC:86043-1001
    Route of AdministrationINTRAVENOUS, SUBCUTANEOUS, INTRAPERITONEAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    SODIUM CHLORIDE (UNII: 451W47IQ8X) (CHLORIDE ION - UNII:Q32ZN48698, SODIUM CATION - UNII:LYR4M0NH37) SODIUM CHLORIDE600 mg  in 100 mL
    POTASSIUM CHLORIDE (UNII: 660YQ98I10) (POTASSIUM CATION - UNII:295O53K152, CHLORIDE ION - UNII:Q32ZN48698) POTASSIUM CHLORIDE40 mg  in 100 mL
    CALCIUM CHLORIDE (UNII: M4I0D6VV5M) (CALCIUM CATION - UNII:2M83C4R6ZB, CHLORIDE ION - UNII:Q32ZN48698) CALCIUM CHLORIDE28 mg  in 100 mL
    SODIUM LACTATE (UNII: TU7HW0W0QT) (LACTIC ACID - UNII:33X04XA5AT, SODIUM CATION - UNII:LYR4M0NH37) SODIUM LACTATE324 mg  in 100 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:86043-1001-1250 mL in 1 CONTAINER
    2NDC:86043-1001-2500 mL in 1 CONTAINER
    3NDC:86043-1001-31000 mL in 1 CONTAINER
    4NDC:86043-1001-43000 mL in 1 CONTAINER
    5NDC:86043-1001-55000 mL in 1 CONTAINER
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    unapproved drug other03/20/2015
    Labeler - Sypharma Pty Ltd (753786292)
    Registrant - Sypharma Pty Ltd (753786292)

Related Drugs